TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11483325

Group type: EXPERIMENTAL
Intervention: HF‐ACC‐RCT with 2 cycles of 5‐FU (600 mg/m(2)/day)/carboplatinum (70 mg/m(2)) on days 1‐5 and 29‐33
Number of subjects: 263

Group type: COMPARATOR
Intervention: HF‐ACC‐RT alone
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: HF‐ACC‐RCT
Number of subjects: 263

Group type: COMPARATOR
Intervention: HF‐ACC‐RT
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Prophylactically given G‐CSF (263 microg, days 15‐19)
Number of subjects: 263
Study: 9740569

Group type: EXPERIMENTAL
Intervention: Intervention practices (n=13) using a nurse facilitator to improve screening for haemoglobin disorders
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control practices (n=13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intervention practices (n=13) adjusted for baseline requests
Number of subjects: 26
Study: 8056991

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clemastine 2 mg (positive control)
Number of subjects: 15
Study: 2569997

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acrivastine 4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clemastine 1 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 782307

Group type: EXPERIMENTAL
Intervention: C-1 group: 32 patients received one dose of i.t. methotrexate at the end of induction treatment and every three months.
Number of subjects: 61

Group type: COMPARATOR
Intervention: C-2 group: 29 patients treated by cranial irradiation (2400 r.) and five doses of i.t. methotrexate after induction of remission.
Number of subjects: 61
Study: 31893730

Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound biofeedback
Number of subjects: 60
Study: 28462585

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26376136

Group type: EXPERIMENTAL
Intervention: Filtered sunlight
Number of subjects: 447

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 447
Study: 23565941

Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No Fresh Frozen Plasma (no FFP)
Number of subjects: 65
Study: 21359424

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type-A (BoNT/A) administered as a 40 μl bolus, lateral to their nose, at 24 hours, 8, 15, 22, 29 or 36 days pre-formalin test (FT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic saline solution 0.9% (control)
Number of subjects: 0
Study: 19343373

Group type: EXPERIMENTAL
Intervention: 1 g of paracetamol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 43
Study: 16772783

Group type: EXPERIMENTAL
Intervention: rhGH (0.05 mg/kg body weight)
Number of subjects: 44
Study: 14706580

Group type: EXPERIMENTAL
Intervention: Cimetidine hydrochloride 1,200 mg daily (H(2)-blocker)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 200 mg daily (H(2)-blocker)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily for 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neither H(2)-blocker nor omeprazole
Number of subjects: 80
Study: 11720833

Group type: EXPERIMENTAL
Intervention: E‐selectin, ICAM‐1, VCAM‐1 serum levels in colorectal cancer patients
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: E‐selectin, ICAM‐1, VCAM‐1 serum levels post-surgery
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pre-operative E‐selectin, ICAM‐1, VCAM‐1 levels
Number of subjects: 63

Group type: COMPARATOR
Intervention: E‐selectin, ICAM‐1, VCAM‐1 levels
Number of subjects: 63
Study: 9159837

Group type: EXPERIMENTAL
Intervention: Stable CAPD patients (n = 11)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bacterial peritonitis patients (n = 5)
Number of subjects: 16
Study: 7957835

Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (methacholine)
Number of subjects: 9
Study: 3546716

Group type: EXPERIMENTAL
Intervention: Metronidazole (1.5 g daily for 10 days)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Tinidazole (1.5 g daily for 10 days)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Ornidazole (1 g daily for 10 days)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Metronidazole (0.5 g daily for 10 days)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Tinidazole (single 2 g dose)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Ornidazole (single 1 g dose)
Number of subjects: 133
Study: 29428546

Group type: EXPERIMENTAL
Intervention: Recommendation menu (vegetarian dish presented as chef's recommendation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive menu (more appealing description of vegetarian dish)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vegetarian menu (vegetarian dishes placed in a separate section)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control menu (all dishes presented in the same manner)
Number of subjects: 0
Study: 27579357

Group type: EXPERIMENTAL
Intervention: Video-based Instruction (VI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional Instruction (CI)
Number of subjects: 50
Study: 24553359

Group type: EXPERIMENTAL
Intervention: Difference-education intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 168
Study: 23521140

Group type: EXPERIMENTAL
Intervention: Articaine 40 mg (20 mg/ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chloroprocaine 40 mg (20 mg/ml)
Number of subjects: 34
Study: 20662773

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 18294804

Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 353

Group type: COMPARATOR
Intervention: Women's Health Education
Number of subjects: 353
Study: 17119689

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral dipyrone (15 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intramuscular dipyrone (15 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: All groups (oral ibuprofen, oral dipyrone, intramuscular dipyrone)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral dipyrone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 75
Study: 12734758

Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high-intensity single-leg pedalling exercise task (PIHIET)
Number of subjects: 13
Study: 11026949

Group type: EXPERIMENTAL
Intervention: New forms of psychological treatment for women newly diagnosed with early-stage breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New forms of psychological treatment for families at risk of maladaptive bereavement
Number of subjects: 0
Study: 8792361

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg, 1 capsule/day for 14 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1284159

Group type: EXPERIMENTAL
Intervention: IS‐5‐MN 20 mg three times daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg three times daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of IS‐5‐MN and gallopamil (same dosages as above)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3969934

Group type: EXPERIMENTAL
Intervention: Weight lifting exercise with RDA protein intake (0.8 g/(kg BW X d))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Weight lifting exercise with 3 X RDA protein intake
Number of subjects: 13

Group type: COMPARATOR
Intervention: No exercise with RDA protein intake
Number of subjects: 13

Group type: COMPARATOR
Intervention: No exercise with 3 X RDA protein intake
Number of subjects: 13
Study: 30267294

Group type: EXPERIMENTAL
Intervention: Eluxadoline (75 mg or 100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29257777

Group type: EXPERIMENTAL
Intervention: Buffalo Concussion Treadmill Test (BCTT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no BCTT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (BCTT and Control)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BCTT
Number of subjects: 54
Study: 27433093

Group type: EXPERIMENTAL
Intervention: Living liver donation (LLD)
Number of subjects: 9598

Group type: EXPERIMENTAL
Intervention: Various factors influencing attitude toward LLD
Number of subjects: 9598
Study: 24652494

Group type: EXPERIMENTAL
Intervention: A/California/7/2009(H1N1)-AS03 vaccine (Ad2 group)
Number of subjects: 6145

Group type: COMPARATOR
Intervention: Nonadjuvanted A/California/7/2009(H1N1) vaccine (NAd2 group)
Number of subjects: 6145

Group type: COMPARATOR
Intervention: A/California/7/2009(H1N1)-AS03 vaccine with saline placebo (control group)
Number of subjects: 6145
Study: 22460572

Group type: EXPERIMENTAL
Intervention: Gabexate
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Nafamostat
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 20147766

Group type: EXPERIMENTAL
Intervention: Treadmill training intervention
Number of subjects: 30
Study: 18049303

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and nisoldipine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nisoldipine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 37
Study: 16635623

Group type: EXPERIMENTAL
Intervention: Strength-training program in addition to conventional physiotherapy (PT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional physiotherapy (PT)
Number of subjects: 39
Study: 12722044

Group type: EXPERIMENTAL
Intervention: Fluvastatin, 40 mg/d (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 10831023

Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg for 4 weeks, followed by 10 mg for 8 weeks
Number of subjects: 17
Study: 8804806

Group type: EXPERIMENTAL
Intervention: Hand insertion of Copper T-380A IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ring forceps insertion of Copper T-380A IUD
Number of subjects: 0
Study: 1354616

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epanolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6824556

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31748187

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) assessment during hospitalization
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Clinical models including Killip class >1, symptom onset-to-wire ≥6 h, LVEF≤35% using index echocardiography, and infarct size ≥40% of LV
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Killip class >1
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Symptom onset-to-wire ≥6 h
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: LVEF≤35% using index echocardiography
Number of subjects: 649
Study: 30777845

Group type: EXPERIMENTAL
Intervention: Video-assisted remote orthopedic consultations (302 consultations)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Standard outpatient consultations at the hospital (257 consultations)
Number of subjects: 389
Study: 28681197

Group type: EXPERIMENTAL
Intervention: School support intervention (tuition, exam fees, uniform costs paid directly to schools)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: School support intervention
Number of subjects: 835

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Intervention and Control
Number of subjects: 835
Study: 25260536

Group type: EXPERIMENTAL
Intervention: Standard technique (ligating splints to orthodontic appliances)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Alternative technique (maxillomandibular screws)
Number of subjects: 314
Study: 23395603

Group type: EXPERIMENTAL
Intervention: Fitness cues on food packages
Number of subjects: 0
Study: 21555774

Group type: EXPERIMENTAL
Intervention: Self-administered teriparatide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20021723

Group type: EXPERIMENTAL
Intervention: Uterine cavity depth measured and uterocervical axis determined on day 2 or 3 of the menstrual cycle (group I)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Uterine cavity depth measured at the time of oocyte retrieval (group II)
Number of subjects: 124
Study: 17189116

Group type: EXPERIMENTAL
Intervention: -20 cm H2O suction
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: -10 cm H2O suction
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Underwater seal
Number of subjects: 29
Study: 15001624

Group type: EXPERIMENTAL
Intervention: Testosterone (Te) 200 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 13
Study: 11689033

Group type: EXPERIMENTAL
Intervention: 3-D condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-D condition
Number of subjects: 0
Study: 9158126

Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retroperitoneal approach
Number of subjects: 100
Study: 7961108

Group type: EXPERIMENTAL
Intervention: Paclitaxel 180 mg/m2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel 75-180 mg/m2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paclitaxel (various doses)
Number of subjects: 18
Study: 3304930

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28
Study: 28831699

Group type: EXPERIMENTAL
Intervention: Active-fluidics Centurion ® phacoemulsification system
Number of subjects: 164

Group type: COMPARATOR
Intervention: Gravity-fluidics Infiniti ® Vision System
Number of subjects: 164
Study: 27059990

Group type: EXPERIMENTAL
Intervention: Continuous-flow cryocompression therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 160
Study: 23907658

Group type: EXPERIMENTAL
Intervention: Baseline endometrial thickness greater than or equal to 5.0 mm
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Baseline endometrial thickness of 1.0-2.99 mm
Number of subjects: 1272
Study: 23585513

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 142
Study: 20016058

Group type: EXPERIMENTAL
Intervention: Social support intervention (home visits and phone calls) for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (phone number of an experienced parent, not trained to give social support)
Number of subjects: 60
Study: 18070947

Group type: EXPERIMENTAL
Intervention: Cell infusion with PBSCs mobilised by G-CSF
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no cell infusion)
Number of subjects: 50
Study: 16174762

Group type: EXPERIMENTAL
Intervention: melphalan-dexamethasone
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: melphalan
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: dexamethasone alone
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: dexamethasone-interferon alpha
Number of subjects: 488

Group type: COMPARATOR
Intervention: melphalan-prednisone
Number of subjects: 488
Study: 14656453

Group type: EXPERIMENTAL
Intervention: Oral yohimbine (20 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral clonidine (150 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11092167

Group type: EXPERIMENTAL
Intervention: Patient medication counseling by a clinical pharmacist prior to discharge
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no additional counseling)
Number of subjects: 37
Study: 9107294

Group type: EXPERIMENTAL
Intervention: Varicose vein stripping
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (minor soft tissue trauma)
Number of subjects: 26
Study: 1489941

Group type: EXPERIMENTAL
Intervention: Lithium citrate syrup
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lithium carbonate tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lithium citrate syrup and Lithium carbonate tablets
Number of subjects: 18
Study: 3551524

Group type: EXPERIMENTAL
Intervention: Nova‐T IUD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLCu250 Short IUD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLCu375 IUD
Number of subjects: 0
Study: 31840547

Group type: EXPERIMENTAL
Intervention: Agricultural diversification (cropping diversity, livestock ownership, cash crop production, pulses production, other vegetables production)
Number of subjects: 1006
Study: 29940926

Group type: EXPERIMENTAL
Intervention: modified Graded Motor Imagery (mGMI) + standard of care (SOC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: standard of care (SOC)
Number of subjects: 66
Study: 29249880

Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 15
Study: 25498245

Group type: EXPERIMENTAL
Intervention: Fish oil (FO, 1.2 g/d n‐3 LCPUFA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sunflower oil (SO)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Predominant bacterial fragments
Number of subjects: 105
Study: 22776413

Group type: EXPERIMENTAL
Intervention: TRC transplantation
Number of subjects: 24

Group type: COMPARATOR
Intervention: GBR
Number of subjects: 24
Study: 21044026

Group type: EXPERIMENTAL
Intervention: fondaparinux
Number of subjects: 127

Group type: COMPARATOR
Intervention: enoxaparin
Number of subjects: 127
Study: 19004197

Group type: EXPERIMENTAL
Intervention: Acupuncture plus acupoint-injection
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral administration of carbamazepine (Control)
Number of subjects: 84
Study: 16645386

Group type: EXPERIMENTAL
Intervention: Mobilization after 3 hours (Group A)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Mobilization after 24 hours (Group B)
Number of subjects: 134
Study: 12533551

Group type: EXPERIMENTAL
Intervention: Noncontact normothermic wound therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 0
Study: 10817610

Group type: EXPERIMENTAL
Intervention: Electric median nerve double-pulse stimulation (10ms and 20ms interstimulus intervals)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intrathalamic SEP
Number of subjects: 13

Group type: COMPARATOR
Intervention: Scalp SEP
Number of subjects: 13
Study: 8592060

Group type: EXPERIMENTAL
Intervention: L-NAME (25 nmol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-NAME and L-NMMA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-NAME (12.5 or 25 pmol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-NAME (25 nmol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-NAME and D-NMMA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (63 pmol)
Number of subjects: 0
Study: 1346719

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ipsapirone (IPS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6405427

Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium (200 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31444538

Group type: EXPERIMENTAL
Intervention: Exercise (EXE) for 5 minutes after walking on a split-belt treadmill
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rest (REST) for 5 minutes after walking on a split-belt treadmill
Number of subjects: 26
Study: 30350297

Group type: EXPERIMENTAL
Intervention: Simeprevir
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Odalasvir
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simeprevir and Odalasvir (combined)
Number of subjects: 30
Study: 26474714

Group type: EXPERIMENTAL
Intervention: Voice training group
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Complete participation in the training program
Number of subjects: 400

Group type: COMPARATOR
Intervention: Students without voice problems at baseline
Number of subjects: 400
Study: 22528829

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation of attention/information processing and executive functions, 3 days/week for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not applicable (control group did not receive cognitive rehabilitation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation of attention/information processing and executive functions
Number of subjects: 20
Study: 21936735

Group type: EXPERIMENTAL
Intervention: PRISM-based joint protection education (PRISM-JP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional joint protection education (C-JP)
Number of subjects: 53
Study: 20565458

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg + Lorazepam 2 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17307749

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (Group I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (Group II)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (Group I and II)
Number of subjects: 24
Study: 15827094

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 125 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (all doses)
Number of subjects: 0